TABLE 1.
Basic features of the included trials.
| First author. Year | Non-small cell lung cancer (NSCLC) | Interventions | Fellow up | Criteria | Outcomes | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TNM | KPS | AST | TP | E/C | M/F | Age | Aidi injection (usages) | GP (dosages) | ||||
| Zou et al. (2006) | IIIb–IV | ≥60 | >3 m | Un | 42/39 | 56/25 | 35–73 | 80 ml, 14 days, 1cycle | G:1 g/m2; P:30 mg/m2 | 6–12 w | WHO,WHO | O1,2,4 |
| Feng et al. (2008) | III–IV | ≥70 | Un | PT | 68/62 | 88/42 | 38–74 | 50 ml, 15 days, 2cycles | G:1 g/m2; P:75 mg/m2 | 6 w | WHO,WHO | O1,2,4,5 |
| Sun et al. (2008) | IIIb–IV | ≥60 | >3 m | PT/RT | 33/30 | 54/9 | 34–73 | 100 ml,14 days,2cycles | G:1 g/m2; P:30 mg/m2 | 1 year | WHO, Un | O1,3 |
| Yang et al. (2008) | III–IV | ≥60 | ≥3 m | Un | 30/27 | 39/18 | 34–82 | 80 ml,8 days,2cycles | G:1 g/m2; P:75 mg/m2 | 6 w | WHO, No | O1,2 |
| Zhao et al. (2008) | III–IV | Un | >3 m | Un | 30/20 | 31/19 | 29–73 | 30 ml,21 days,3cycles | G:1 g/m2;P:60–80 mg/m2 | 9 w | WHO,WHO | O1,2,4 |
| Lv et al. (2009) | IIIb–IV | ≥60 | ≥3 m | Un | 30/30 | 42/18 | 45–70 | 80 ml,10 days,2cycles | G:1 g/m2; P:60–80 mg/m2 | 6 w | WHO,WHO | O1,2,4 |
| Song et al. (2009) | III–IV | >60 | >3 m | PT | 30/30 | 36/24 | 53–76 | 50 ml,14 days,2cycles | G:1 g/m2; P:30 mg/m2 | 6 w | WHO,WHO | O1,2,4 |
| Wang. (2009) | IIIa–IV | ≥60 | >3 m | Un | 32/27 | 48/11 | Un | Un,10 days,2cycles | G:1 g/m2; P:20 mg/m2 | 6 w | WHO,WHO | O1,O4 |
| Wen et al. (2009) | IIIa–IV | Un | >3 m | PT/RT | 38/38 | 52/24 | 32–77 | 50 ml,8–10 days,2cycles | G:1 g/m2; P:75 mg/m2 | 6 w | WHO,WHO | O1,2,4 |
| Zhang. (2009) | IIIb–IV | ≥60 | >3 m | PT/RT | 32/31 | 44/19 | 31–79 | 80 ml,14 days,2cycles | G:1 g/m2; P:80 mg/m2 | 6 w | WHO,WHO | O1,2,4 |
| Hong et al. (2010) | IIIb–IV | ≥60 | ≥3 m | PT | 90/70 | 82/78 | 38–70 | 60 ml,14 days,2cycles | G:1 g/m2; P:25 mg/m2 | 6 w | WHO,WHO | O1,2,4 |
| Hou and Zhang. (2010) | III–IV | ≥60 | ≥3 m | Un | 40/38 | 49/29 | 32–79 | 50 ml,14 days,2cycles | G:1 g/m2; P:25 mg/m2 | 6 w | WHO,WHO | O1,2,4 |
| Li et al. (2010) | III–IV | >60 | >3 m | Un | 36/36 | 39/33 | 29–75 | 50–100 ml,15 days,2cycles | G:1 g/m2; P:30 mg/m2 | 6 w | WHO,WHO | O1,2,4 |
| Liu et al. (2010) | III–IV | >60 | >3 m | Un | 32/32 | 37/27 | 45–75 | 50 ml,14days,4cycles | G:1 g/m2; P:30 mg/m2 | 12 w | WHO, No | O1,4 |
| Shi et al. (2010) | IIIa–IV | ≥60 | ≥3 m | PT | 28/28 | 47/9 | 48–72 | 50 ml,14days,2cycles | G:1 g/m2; P:30 mg/m2 | 6 w | WHO,WHO | O1,2,4 |
| Ding et al. (2011) | III–IV | >50 | >3 m | Un | 18/22 | 27/13 | Un | 50 ml,10days,2cycles | G:1.4 g/m2; P:40 mg/m2 | 8 w | Un, WHO | O1,2,4 |
| Fan et al. (2011) | IIIb–IV | ≥60 | >3 m | Un | 41/38 | 54/25 | 39–73 | 50 ml,21 days,2-4cycles | G:1 g/m2; P:30 mg/m2 | 6–12 w | WHO, No | O1,2 |
| He et al. (2011) | IIIb–IV | ≥60 | >3 m | Un | 29/23 | 29/23 | 21–74 | 50–100 ml,15 days,2-3cycles | G:1 g/m2; P:75 mg/m2 | 8–11 w | WHO,WHO | O1,2,4 |
| Jiang et al. (2011) | IIIb–IV | ≥60 | >3 m | PT | 32/30 | 39/23 | 60–75 | 100 ml,14days,2cycles | G:1 g/m2; P:80 mg/m2 | 6 w | WHO, No | O1,2,5 |
| Lu et al. (2011) | IIIb–IV | ≥60 | >6 m | Un | 34/34 | 39/29 | 40–76 | 100 ml,14 days,2cycles | G:1 g/m2; P:80 mg/m2 | 6 w | WHO, Un | O1,2,4 |
| Wu and He. (2011) | III–IV | Un | Un | Un | 30/30 | 41/19 | 45–77 | 100 ml,16 days,2cycles | G:1 g/m2; P:30 mg/m2 | 6 w | WHO, No | O1 |
| Fu. (2012) | IIIb–IV | Un | >3 m | Un | 35/35 | Un | 61–84 | 50 ml,14 days,2cycles | G:1 g/m2; P:30 mg/m2 | 6 w | WHO, Un | O1,4 |
| Pei. (2012) | IIIb–IV | Un | Un | PT | 40/40 | 47/33 | 39–72 | 50 ml,8 days,2cycles | G:1 g/m2; P:20 mg/m2 | 6 w | RECIST | O1 |
| Sun et al. (2012) | IIIb–IV | Un | >3 m | Un | 34/34 | 42/26 | 60–86 | 50 ml,10 days,2cycles | G:1 g/m2; P:30 mg/m2 | 6 w | RECIST, CTCAE | O1,2,4 |
| Wang. (2012) | III–IV | ≥60 | >3 m | Un | 25/24 | 35/14 | 56.8 ± 9.1/57.8 ± 10.2 | 60 ml,14 days,3cycles | G:1 g/m2; P:25 mg/m2 | 9 w | WHO, Un | O1,4 |
| Wang and Peng. (2012) | IIIb–IV | ≥70 | ≥3 m | Un | 36/36 | 46/26 | 32–74 | 80 ml,10 days,2-4cycles | G:1 g/m2; P:40 mg/m2 | 6–12 w | RECIST, WHO | O1,2,4 |
| Xu et al. (2012) | IIIb–IV | ≥70 | Un | Un | 33/33 | 36/30 | Un | 80 mg,10 days,4cycles | G:1.25 g/m2;P:100 mg/m2 | 13 w | RECIST, WHO | O1,4 |
| Zhang. (2012) | IIIb–IV | ≥60 | >3 m | Un | 41/42 | 63/20 | 57.2 ± 9.4/58.2 ± 10.3 | 60 ml,14 days,3cycles | G:1 g/m2; P:25 mg/m2 | 9 w | WHO, Un | O1,4 |
| Cai et al. (2013) | IIIa–IV | ≥60 | Un | Un | 19/19 | 21/17 | 36–68 | 50–100 ml,15 days,2cycles | G:1 g/m2; P:30mg/m2 | 6 w | Un | O4 |
| Ju et al. (2013) | IIIb–IV | Un | >3 m | Un | 34/34 | 36/32 | 61–81 | 50 ml,14 days,2cycles | G:1 g/m2; P:50 mg/m2 | 6 w | WHO, Un | O1,2,4 |
| Lai. (2013) | IIIb–IV | Un | Un | Un | 70/70 | 73/67 | 45–79 | 50 ml,14 days,>2cycles | G:1 g/m2; P:30 mg/m2 | Un | WHO,WHO | O1,2,4 |
| Xu et al. (2013) | IIIb–IV | Un | Un | Un | 38/42 | 55/25 | 39–81 | 50 ml/14 days/3cycles | G:1 g/m2; P:30 mg/m2 | 9 w | WHO,WHO | O1,2,4,5 |
| Li and Yang. (2014) | IIIb–IV | Un | >3 m | PT | 27/27 | 32/22 | 34–68 | 50ml/8–10 days/4cycles | G:1 g/m2; P:75 mg/m2 | 12 w | RECIST, CTCAE | O1,3,4 |
| Liu and Zhao. (2014) | IIIb–IV | ≥60 | ≥3 m | Un | 43/43 | 53/33 | 39–73 | 50ml/8–10 days/2cycles | G:1 g/m2; P:50 mg/m2 | 6 w | WHO,WHO | O1,4 |
| Liu and Zhang. (2014) | IIIb–IV | Un | Un | Un | 24/24 | 30/18 | 35–80 | 60 ml/21 days/2cycles | G:0.2 g/m2; P:25 mg/m2 | 6 w | Un, Un | O2,4 |
| Wen. (2014) | IIIb–IV | ≥60 | ≥3 m | Un | 45/45 | 64/26 | 61–81 | 50 ml/21 days/2cycles | G:1 g/m2; P:50 mg/m2 | 6 w | RECIST, CTCAE | O1,2,4 |
| Cheng et al. (2014) | IIIb–IV | ≥70 | ≥3 m | PT | 49/52 | 78/23 | 27–74 | 50–100 ml/10 days/2cycles | G:1–1.25 g/m2;P:25 mg/m2 | 2 years | RECIST, WHO | O1-4 |
| Li et al. (2014) | IIIb–IV | >60 | >3 m | Un | 30/30 | 28/32 | 40–81 | 50 ml/10 days/2cycles | G:1 g/m2; P:50 mg/m2 | Un | WHO, Un | O1,2,4 |
| Zhang. (2014) | III–IV | Un | Un | Un | 64/64 | 68/60 | 57–79 | 50 ml/10days/Un | G:1 g/m2; P:30 mg/m2 | 8 w | ELISA,FCM | O5 |
| Han et al. (2015) | IIIb–IV | Un | Un | Un | 36/36 | 39/33 | 48–67 | 50 ml,Un,3cycles | G:1 g/m2; P:Un | 12 w | WHO, Un, FCM | O1,4,5 |
| Li. (2015) | IIIb–IV | ≥60 | ≥3 m | Un | 20/20 | 24/16 | 45–74 | 50 ml/10 days/2cycles | G:1 g/m2; P:80 mg/m2 | 6 w | WHO, Un | O2,4,5 |
| Ning et al. (2015) | III–IV | Un | Un | RT | 31/31 | 49/13 | 45–75 | 50 ml/14 days/3cycles | G:1 g/m2; P:75 mg/m2 | 1 year | WHO,WHO | O1,3,4 |
| Zhang. (2015) | III–IV | Un | Un | Un | 39/32 | 37/34 | 60–83 | 50 ml/10 days/2cycles | G:1 g/m2; P:30 mg/m2 | 8 w | RECIST, CTCAE | O1,4 |
| Zhao et al. (2015) | III–IV | ≥70 | >3 m | Un | 43/43 | 58/28 | 43–79 | 100 ml/10 days/Un | G:1 g/m2; P:25 mg/m2 | Un | WHO,WHO,FCM | O1,2,4,5 |
| Zhu. (2015) | IIIb–IV | ≥60 | >3 m | Un | 21/21 | 22/20 | 60–75 | 100 ml/14 days/Un | G:1 g/m2; P:25 mg/m2 | Un | WHO,WHO | O1,4 |
| Chen. (2016) | III–IV | >60 | >3 m | Yes | 30/30 | 36/24 | 42–76 | 80 ml/8 days/2cycles | G:1 g/m2; P:25 mg/m2 | 6 w | WHO | O1 |
| Fang. (2016) | III–IV | ≥70 | Un | Un | 45/45 | Un/Un | 40–70 | 50 ml/10 days/2cycles | G:1 g/m2; P:75 mg/m2 | 6 w | WHO,CTCAE | O1,4 |
| Li et al. (2016) | IIIb–IV | ≥60 | >3 m | Un | 47/47 | 52/42 | 40–70 | 50–100 ml/28 days/1cycles | G:1 g/m2; P:30 mg/m2 | 12 w | WHO, Un, FCM | O1,2,4,5 |
| Li. (2016) | III–IV | >60 | >6 m | Un | 35/35 | 43/27 | 44–82 | 100 ml/14 days/1cycles | G:1 g/m2; P:80 mg/m2 | 6 w | WHO,WHO | O1,2,4 |
| Ma and Jiang. (2016) | III–IV | >60 | >3 m | Un | 33/35 | 39/29 | Un | 60 ml/14 days/1cycles | G:1 g/m2; P:25 mg/m2 | Un | WHO, Un | O1,4 |
| Zhang. (2016a) | III–IV | Un | Un | Un | 19/19 | 21/17 | 45–76 | 50 ml/28 days/1cycles | G:1 g/m2; P:25 mg/m2 | 6 w | WHO, Un | O1,2,4 |
| Zhang. (2016b) | IV | Un | >3 m | PT | 25/25 | Un/Un | 32–70 | 50 ml/10 days/4cycles | G:1 g/m2; P:75 mg/m2 | 12 w | RECIST, WHO | O1,2,4 |
| Huang et al. (2017) | IIIb–IV | ≥60 | ≥6 m | Un | 39/40 | 46/33 | 49–70 | 60 ml/21 days/3cycles | G:1 g/m2; P:25 mg/m2 | 9 w | RECIST,WHO,FCM | O1,4,5 |
| Ma. (2017) | IIIb–IV | ≥60 | ≥6 m | Un | 42/42 | 55/29 | 44–75 | 50ml/Un/4cycles | G:1 g/m2; P:75 mg/m2 | 16 w | WHO, Un, FCM | O1,4,5 |
| Su. (2017) | IIIb–IV | Un | ≥3 m | Un | 40/39 | 45/34 | 40–70 | 50 ml/21 days/2cycles | G:1 g/m2; P:30 mg/m2 | 6 w | RECIST, Un, FCM | O1,4,5 |
| Wu and Chen. (2017) | III–IV | Un | Un | Un | 67/68 | 83/52 | 43–71 | 100 ml/10 days/4cycles | G:1 g/m2; P:20 mg/m2 | 12 w | WHO, Un | O1,4 |
| Wu et al. (2017b) | III–IV | Un | Un | Un | 109/109 | 137/79 | 32–72 | 50 ml/14 days/3cycles | G:1 g/m2; P:80 mg/m2 | 9 w | Un, FCM | O2,4,5 |
| Zhang et al. (2017) | III–IV | Un | Un | Un | 54/54 | 64/40 | 46–79 | 60–100 ml/10 days/4cycles | G:1 g/m2; P:30 mg/m2 | 12 w | WHO, Un | O1,2,4 |
| Lv et al. (2018) | III–IV | >70 | >3 m | Un | 30/30 | 35/25 | 56–75 | 50 ml/14 days/Un | G:1 g/m2; P:25 mg/m2 | Un | WHO,FCM | O1,5 |
| Zhang. (2018) | III–IV | Un | ≥5m | Un | 40/40 | 43/27 | 38–72 | 60 ml/10 days/2cycles | G:1 g/m2; P:25 mg/m2 | 6 w | Un | O4 |
| Zhou. (2018) | III–IV | Un | ≥3 m | Un | 58/58 | 63/53 | 41–70 | 50 ml/20 days/Un | G:1 g/m2; P:25 mg/m2 | Un | RECIST, Un | O1,4 |
| Su and Zhang. (2019) | III–IV | ≥60 | ≥3 m | Un | 41/41 | 54/28 | 42–78 | Un/21 days/4-6cycles | G:1–1.25 g/m2; P:50 mg/m2 | 12–18 w | RECIST, Un | O1,2,4 |
| Liu et al. (2019) | IIIb–IV | Un | Un | Un | 44/44 | 54/34 | 42–76 | 50ml/Un/2cycles | G:1 g/m2; P:20 mg/m2 | Un | Un | O1,5 |
| Zhao and Li. (2010) | III–IV | Un | ≥3 m | PT | 43/43 | 55/31 | 64.0 ± 2.3/63.5 ± 2.6 | 50 ml/21dayays/2cycles | G:1.0 g/m2; P:80 mg/m2 | 6 w | WHO, Un | O1,3,5 |
| Chen. (2020) | III–IV | Un | Un | Un | 49/49 | 51/47 | 61–86 | 50–100 ml/10 days/Un | G:1–1.25 g/m2; P:25 mg/m2 | Un | RECIST, Un | O1,2,4 |
| Geng et al. (2020) | III–IV | ≥70 | ≥3 m | Un | 45/45 | 61/29 | 44–79 | 50 ml/14 days/4cycles | G:1.0 g/m2; P:30 mg/m2 | 8 w | WHO, Un | O1,4 |
| Tan et al. (2020) | IIIb–IV | >60 | ≥3 m | Un | 60/60 | 78/42 | 60–80 | 50 ml/10 days/2cycles | G:1.0 g/m2; P:30 mg/m2 | 6 w | RECIST,WHO,FCM | O1,2,4,5 |
| Guo. (2020) | IIIb–IV | Un | ≥3 m | Un | 51/51 | 58/44 | 43–75 | 60 ml/14 days/4cycles | G:1.0 g/m2; P:25 mg/m2 | 12 w-1 year | WHO,FCM | O3,4,5 |
| Xu and Li. (2020) | IIIb–IV | Un | Un | Un | 51/45 | 53/37 | 42–82 | 60 ml/21 days/3cycles | G:1.0 g/m2; P:25 mg/m2 | 9 w | WHO | O1,2 |
| Xu. (2020) | III–IV | Un | >6 m | Un | 40/40 | 43/27 | 49–72 | 50–100 ml/21 days/2cycles | G:1.0 g/m2; P:20 mg/m2 | 6 w | RECIST,Un,FCM | O1,4,5 |
Note: GP: Gemcitabine and cisplatin; E: Experimental group (Aidi plus GP); C: Control group (GP alone); KPS score: Karnofsky Performance Status score; TP: treatment process; PT: primary treatment; RT: retreatment; AST: anticipated survival time; M: male; F: female; WHO: World Health Organization guidelines for solid tumor responses; RECIST: Response Evaluation Criteria in Solid Tumors; FCM: flow cytometry; O1: clinical efficacy included ORR and DCR; O2: quality of life (QOL); O3: patient survival; O4: adverse drug reactions (ADRs); and O5: antitumor immunity.